The future of patent-based injunctions in doubt in India after explosive Delhi High Court ruling 13 Feb 17
Bayer has failed to block an Indian generic rival from exporting an erectile dysfunction drug in a case that one observer says breaks new ground in considering how to weigh public interest issues relating to the grant or not of patent-based injunctions. The ruling comes ahead of an annual pitched battle over the country’s pharmaceutical patent laws, as well as IAM’s first conference in the country at the end of this month.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM is a high quality magazine with in-depth articles about intellectual asset management not found in any other publication. It adds value to our profession!
Director of the office of technology licensing
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email